Gyre Therapeutics Q1 revenue $22.5M, net loss $9.9M; Cullgen acquisition closed; NDA for F351 submitted

GYRE THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.10 vs consensus -$0.07 ▼ miss (-33.7%)

Q1 2026 revenue $22.5M (+2% YoY); GAAP basic EPS $(0.10); net loss $9.9M vs $3.7M net income YoY.
Non-GAAP adjusted net loss $4.2M vs adjusted net income $2.9M in Q1 2025.
Completed acquisition of Cullgen for ~$300M all-stock, expanding pipeline into inflammatory diseases and cancers.
NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 with priority review.
FY 2026 revenue guidance reaffirmed at $100.5-$111.0M; first patient enrolled in Phase 2/3 trial for radiation-induced lung injury.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: revenue $22.5 million, EPS $(0.10). Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $22.5 million
EPS: $(0.10)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s

View on SEC.gov

Browse all earnings releases →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-209789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.